Navigation Links
Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
Date:11/25/2008

TOKYO and CAMBRIDGE, England, November 26 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that it has out-licensed its IP and Know How relating to the RS(+) isomer of mefloquine to Treague Ltd. ("Treague"), a Cambridge, UK based pharma company, for the treatment and prophylaxis of malaria.

Mefloquine is a highly efficacious anti-malarial drug that is approved in its racemic form for both treatment (in combination with artesunate) and prophylaxis (as monotherapy) of malaria. Though its efficacy and long half-life make racemic mefloquine a particularly attractive anti-malarial drug, its clinical utility has been compromised by CNS side effects. However, it is hypothesised, based on the stereoselective nature of mefloquine's receptor binding that RS(+) mefloquine has the potential for substantially reduced CNS side effect liability. Treague is collaborating with Medicines for Malaria Venture (MMV), a Geneva-based not-for-profit organization dedicated to reducing the burden of malaria, to develop RS(+) mefloquine for the treatment of malaria in malaria endemic countries. In addition, Treague plans to develop RS(+) mefloquine for the prophylaxis of malaria for commercial sale.

Based on its cytokine modulatory activity, Sosei were developing RS(+) mefloquine as AD 452 for the treatment of rheumatoid arthritis. However, despite an excellent safety profile, clinical studies failed to demonstrate sufficient efficacy in this indication and the AD 452 programme was terminated in 2006.

"We are delighted to contribute to the development of a potentially safer and better tolerated anti-malarial," said Shinichi Tamura, CEO of Sosei.

Dr Robert Tansley, Treague's Development & Medical Director said, "By building on the pre-clinical and clinical work conducted by Sosei, we have the opportunity to rapidly develop an
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
2. Sosei Announces Outcome of Strategy Review
3. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
4. Genoptix Announces Participation at the Twentieth Annual Piper Jaffray Healthcare Conference
5. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
6. Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President
7. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
8. Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
9. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
10. CorVel Announces MSA Agent Services
11. Health Robotics Announces $60M Investment by Devon International Group and ITOCHU Inc. in the CytoCare(TM) and i.v.Station(TM PENDING) Robots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Pipette.com has added ... to their comprehensive portfolio of Eppendorf products. , The ... purchase a Centrifuge 5424/5424 R and receive the following:, ... Eppendorf Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Geneva, Switzerland (PRWEB) January 22, 2015 ... for characterized mammalian Research Cell Banks (RCBs) used for ... generated Research Cell Banks will include Next-Generation Sequencing ... cell’s genetic architecture de-risks biologic manufacturing by ensuring the ...
(Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... to rule the world, the honey bee, Apis mellifera, ... demonstrates that when these honey bees arrive in a ... from the genetic endowment of their predecessors. , ... in Proceedings of the National Academy of Sciences. , ...
... Thermo Fisher,Scientific Inc. (NYSE: TMO ), the ... press conference on Monday, March 3, 2008, at,12:30 p.m. ... be held this year in New Orleans., Marc ... provide an overview of the company, and Dr. Ian ...
... $160 million or more, up from $42 ... - First HGS product sales expected with delivery of ABthrax(TM) to ... - First Albuferon(R) Phase 3 data expected late 2008 -, - Enrollment completed ... ...
Cached Biology Technology:Honey bee invaders exploit the genetic resources of their predecessors 2Honey bee invaders exploit the genetic resources of their predecessors 3Thermo Fisher Scientific to Webcast Press Conference at PITTCON 2008 2Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 2Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 3Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 4Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 5Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 6Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 7Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 8Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 9Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 10Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 11
(Date:12/19/2014)... LaunchKey , the first decentralized mobile authentication and authorization ... era, today announced the close of $3 million in ... Metamorphic Ventures with participation from ENIAC Ventures, Crosslink Capital, ... has raised $4 million to date, and will use ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research and Markets ... of the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming in ... in biomedical applications. Chemical sensors help in recording of ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... Ore. Wildfire, insect outbreaks and hurricanes destroy huge ... of carbon dioxide entering the atmosphere, but scientists are ... affect their climate impact. Researchers conclude in a ... amount of energy reflected back into space, is important ...
... Researchers at Case Western Reserve University School of Medicine ... to two weeks after donor death work as well as ... National Eye Institute has awarded a $12.3 million grant to ... nationwide meets current needs about 40,000 transplants in 2010. ...
... (Boston) The National Institutes of Health (NIH) ... and the College of Engineering (COE) a five ... Caroline Genco, PhD, research director, Section of Infectious ... is the principal investigator alongside Selim nl, PhD, ...
Cached Biology News:'Albedo effect' in forest disturbances can cause added warming, bonus cooling 2'Albedo effect' in forest disturbances can cause added warming, bonus cooling 3Study seeks to widen corneal transplant window 2Study seeks to widen corneal transplant window 3NIH training grant awarded to Boston University School of Medicine and College of Engineering 2
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
...
...
... isomers are predominantly used for labeling proteins, ... labeling peptides and nucleotides because they give ... often required in the conjugation processes. 5-TAMRA ... labeling peptides and proteins. 6-TAMRA is predominately ...
Biology Products: